Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 19, 2026

David Ebrahimzadeh and Corniche Capital Announce Up to 400,000 Square Feet of Build-to-Suit Industrial Space at Los Morros Business Park in Los Lunas, New Mexico

View original at globenewswire.com
David Ebrahimzadeh and Corniche Capital Announce Up to 400,000 Square Feet of Build-to-Suit Industrial Space at Los Morros Business Park in Los Lunas, New Mexico NEW YORK, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The economic incentives New Mexico offers make this one of the most cost-effective locations in the country to build and operate

    80% confidence
  • Los Lunas sits at the center of everything industrial tenants need right now: power, transportation, labor, and a state government that actively wants to help businesses grow

    80% confidence
  • With up to 400,000 square feet of build-to-suit capacity, Corniche can deliver custom-configured facilities for everything from food-grade cold storage to defense manufacturing to hyperscale data centers

    80% confidence
  • New Mexico is one of the most financially attractive states in the country for industrial users

    80% confidence
  • Combined incentive package can reduce all-in cost of occupancy by 20% to 40% compared to competing markets

    80% confidence
  • Corniche is not offering generic warehouse space but the ability to design and construct a facility precisely tailored to a tenant's operational requirements

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com